Literature DB >> 8398153

Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system.

R J Buckanovich1, J B Posner, R B Darnell.   

Abstract

Paraneoplastic opsoclonus-ataxia, a disorder of motor control, develops in breast or lung cancer patients who harbor an antibody (Ri) that recognizes their tumors and a nuclear neuronal protein of 55 kd. We have characterized a gene, Nova, encoding an antigen recognized by the Ri antibody. Nova encodes a novel, highly conserved protein, homologous to the RNA-binding protein hnRNP K, the yeast splicing protein MER1, and a motif in several retroviral proteases. Northern blot analysis detects Nova transcripts only in brain, and several alternatively spliced forms are present in brain and tumor cells. Nova expression is restricted to the ventral brain stem and spinal cord in E18 mice. Since Nova encodes a target antigen in the motor disorder paraneoplastic opsoclonus-ataxia that is expressed in the developing subcortical motor system, it is a likely participant in both the pathogenesis of paraneoplastic opsoclonus-ataxia and the developmental biology of the motor system. The homology between Nova and hnRNP K suggests that Nova regulates RNA splicing or metabolism in a specific subset of developing neurons.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8398153     DOI: 10.1016/0896-6273(93)90077-5

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  101 in total

1.  Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer.

Authors:  A O Güre; E Stockert; M J Scanlan; R S Keresztes; D Jäger; N K Altorki; L J Old; Y T Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

2.  The tetranucleotide UCAY directs the specific recognition of RNA by the Nova K-homology 3 domain.

Authors:  K B Jensen; K Musunuru; H A Lewis; S K Burley; R B Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

3.  U1 snRNP-dependent function of TIAR in the regulation of alternative RNA processing of the human calcitonin/CGRP pre-mRNA.

Authors:  Hui Zhu; Robert A Hasman; Katherine M Young; Nancy L Kedersha; Hua Lou
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

4.  Determination and augmentation of RNA sequence specificity of the Nova K-homology domains.

Authors:  Kiran Musunuru; Robert B Darnell
Journal:  Nucleic Acids Res       Date:  2004-09-14       Impact factor: 16.971

Review 5.  Emerging mechanisms and consequences of calcium regulation of alternative splicing in neurons and endocrine cells.

Authors:  Aleh Razanau; Jiuyong Xie
Journal:  Cell Mol Life Sci       Date:  2013-06-26       Impact factor: 9.261

6.  An uncommon paraneoplastic Ri-positive opsoclonus-myoclonus-like syndrome and stiff-person syndrome with elevated glutamate/GABA ratio in the cerebrospinal fluid after breast cancer.

Authors:  A Thümen; A Moser
Journal:  J Neurol       Date:  2010-02-23       Impact factor: 4.849

7.  Nova autoregulation reveals dual functions in neuronal splicing.

Authors:  B Kate Dredge; Giovanni Stefani; Caitlin C Engelhard; Robert B Darnell
Journal:  EMBO J       Date:  2005-03-31       Impact factor: 11.598

8.  Qualitative evidence of anti-Ri specific intrathecal antibody synthesis and quantification of anti-Ri antibodies in serial samples from a patient with anti-Ri syndrome.

Authors:  O Stich; S Rauer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

Review 9.  Control of alternative pre-mRNA splicing by Ca(++) signals.

Authors:  Jiuyong Xie
Journal:  Biochim Biophys Acta       Date:  2008-01-17

Review 10.  Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain.

Authors:  R B Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.